The Korean Journal of Medicine

  • 제86권6호
  • /
  • Pages.686-694
  • /
  • 2014
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

바소프레신 제2수용체 길항제의 임상 적용

Clinical Application of V2 Receptor Antagonists

  • 오일환 (한양대학교 의과대학 내과학교실) ;
  • 김근호 (한양대학교 의과대학 내과학교실)
  • Oh, Il Hwan (Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Kim, Gheun-Ho (Department of Internal Medicine, Hanyang University College of Medicine)
  • 발행 : 2014.06.01
⟨ 이전 논문 다음 논문 ⟩

초록

Hyponatremia results from a relative excess of total body water compared with the sodium content. Except for primary polydipsia, vasopressin activation plays a major role in pathogenesis of water retention. Consequently, the increase of solute-free water clearance by inactivating vasopressin action would be a more reasonable therapeutic approach than the addition of sodium. The V2 vasopressin receptor is mainly localized to the collecting ducts in the kidney and causes water reabsorption via water channels. Selective V2 receptor antagonists or vaptans were recently introduced to clinical practices and may be useful for correcting dilutional hyponatremia. Clinical trials have shown that vaptans are effective in increasing the serum sodium concentration in patients with syndrome of inappropriate anti-diuresis and congestive heart failure and that they might be safe as long as patients are allowed free accesses to water. However, the indications for using vaptans need to be more refined, and the question of their long-term cost-effectiveness should be answered. In addition, the potential roles of vaptans in ameliorating the growth of cysts in polycystic kidney disease, saving diuretics in edematous disorders, and retarding the progression of chronic kidney disease are being explored.

키워드

참고문헌

  1. Edelman IS, Leibman J, O'Meara MP, Birkenfeld LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 1958;37:1236-1256. https://doi.org/10.1172/JCI103712
  2. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006;69:2124-2130. https://doi.org/10.1038/sj.ki.5000432
  3. Kim GH, Ecelbarger CA, Mitchell C, Packer RK, Wade JB, Knepper MA. Vasopressin increases Na-K-2Cl cotransporter expression in thick ascending limb of Henle's loop. Am J Physiol 1999;276(1 Pt 2):F96-103.
  4. Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 2000;319:240-244. https://doi.org/10.1097/00000441-200004000-00007
  5. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986;314:1535-1542. https://doi.org/10.1056/NEJM198606123142402
  6. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994;4:1522-1530.
  7. Ablij HC, Innemee G, Tamsma JT, Meinders AE. Intravenous fluid therapy taken into theoretical and practical consideration: physiology revisited. Neth J Med 2001;58:111-122. https://doi.org/10.1016/S0300-2977(01)00082-1
  8. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82:205-244. https://doi.org/10.1152/physrev.00024.2001
  9. Lehrich RW, Ortiz-Melo DI, Patel MB, Greenberg A. Role of vaptans in the management of hyponatremia. Am J Kidney Dis 2013;62:364-376. https://doi.org/10.1053/j.ajkd.2013.01.034
  10. Miranda CA, Lee JW, Chou CL, Knepper MA. Tolvaptan as a tool in renal physiology. Am J Physiol Renal Physiol 2014;306:F359-366. https://doi.org/10.1152/ajprenal.00330.2013
  11. Manning M, Lammek B, Kolodziejczyk AM, Seto J, Sawyer WH. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin. J Med Chem 1981;24:701-706. https://doi.org/10.1021/jm00138a012
  12. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002;29:1-9. https://doi.org/10.1677/jme.0.0290001
  13. Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent: a novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653-2659. https://doi.org/10.1172/JCI116881
  14. Ambrosy A, Goldsmith SR, Gheorghiade M. Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother 2011;12:961-976. https://doi.org/10.1517/14656566.2011.567267
  15. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000;292:288-294.
  16. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006;290:F273-278. https://doi.org/10.1152/ajprenal.00195.2005
  17. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105:787-791. https://doi.org/10.1111/j.1476-5381.1992.tb09058.x
  18. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287:860-867.
  19. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331. https://doi.org/10.1001/jama.297.12.1319
  20. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-1343. https://doi.org/10.1001/jama.297.12.1332
  21. Hauptman PJ, Burnett J, Gheorghiade M, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013;19:390-397. https://doi.org/10.1016/j.cardfail.2013.04.001
  22. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:1540-1545. https://doi.org/10.1016/j.jacc.2008.08.013
  23. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112. https://doi.org/10.1056/NEJMoa065181
  24. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-732. https://doi.org/10.1530/EJE-10-1078
  25. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-712. https://doi.org/10.1681/ASN.2009080857
  26. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323-1326. https://doi.org/10.1038/nm935
  27. Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005;16:846-851. https://doi.org/10.1681/ASN.2004121090
  28. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:102-108. https://doi.org/10.1681/ASN.2007060688
  29. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-2418. https://doi.org/10.1056/NEJMoa1205511
  30. Food and Drug Administration. Samsca (tolvaptan): drug warning-potential risk of liver injury [Internet]. Silver Spring: Food and Drug Administration, c2013 [cited 2013 Jan 31]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm.
  31. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91:2145-2152. https://doi.org/10.1210/jc.2005-2287
  32. Annane D, Decaux G, Smith N; Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci 2009;337:28-36. https://doi.org/10.1097/MAJ.0b013e31817b8148
  33. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007;27:447-457. https://doi.org/10.1159/000106456
  34. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf) 2008;69:159-168. https://doi.org/10.1111/j.1365-2265.2007.03149.x
  35. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005;95(9A):8B-13B.
  36. Goldsmith SR, Elkayam U, Haught WH, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;14:641-647. https://doi.org/10.1016/j.cardfail.2008.06.003
  37. Peri A. Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 2013;98:1321-1332. https://doi.org/10.1210/jc.2012-4082
  38. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-191. https://doi.org/10.1053/jhep.2003.50021
  39. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-939. https://doi.org/10.1053/gast.2003.50143
  40. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, nonpeptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-1621. https://doi.org/10.1016/j.jacc.2005.11.071
  41. Abraham WT, Decaux G, Josiassen RC, et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int 2012;82:1215-1222. https://doi.org/10.1038/ki.2012.274
  42. Abraham WT, Hensen J, Gross PA, et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney Int 2012;82:1223-1230. https://doi.org/10.1038/ki.2012.275
  43. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006;1:1154-1160. https://doi.org/10.2215/CJN.00160106
  44. Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008;48:204-213. https://doi.org/10.1002/hep.22293
  45. Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010;53:283-290. https://doi.org/10.1016/j.jhep.2010.02.036
  46. Gines P, Wong F, Watson H, et al. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010;31:834-845.
  47. Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012;61:108-116. https://doi.org/10.1136/gutjnl-2011-300157
  48. Dasta JF, Chiong JR, Christian R, Lin J. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract (1995) 2012;40:7-14.
  49. Chiong JR, Kim S, Lin J, Christian R, Dasta JF. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ 2012;15:276-284. https://doi.org/10.3111/13696998.2011.643329
  50. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010;5:275-280. https://doi.org/10.2215/CJN.06120809
  51. Ayus JC, Negri AL, Kalantar-Zadeh K, Moritz ML. Is chronic hyponatremia a novel risk factor for hip fracture in the elderly? Nephrol Dial Transplant 2012;27:3725-3731. https://doi.org/10.1093/ndt/gfs412
  52. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 2008;19:1721-1731. https://doi.org/10.1681/ASN.2008010021
  53. Shimizu M, Ishikawa S, Yachi Y, et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol 2013 Nov 19 [Epub]. DOI:10.1007/s00467-013-2687-1.
  54. Bolignano D, Zoccali C. Vasopressin beyond water: implications for renal diseases. Curr Opin Nephrol Hypertens 2010;19:499-504. https://doi.org/10.1097/MNH.0b013e32833d35cf
  55. Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013;9:223-239. https://doi.org/10.1038/nrneph.2013.22